Latache manages to elect a majority on the Oncoclinicas board.

With support from Arc Capital, Capitalo, Banco Original, and Santander, five of the seven chosen members are from a slate proposed by the asset manager, according to NeoFeed.

Guilherme Guilherme 07/01/26 12:23

Latache manages to elect a majority on the Oncoclinicas board.

Oncoclínicas is valued at R$ 3 billion.

Oncoclínicas shareholders elected the company's new board of directors at an Extraordinary General Meeting (EGM) held on the morning of Wednesday, January 7th.

With a two-year term, five names were elected from the slate proposed by shareholders Latache and Nova Almeida: Marcel Cecchi, Marcelo Curti, Eduardo Couto, Bruno Ferrari , who will be vice-president of the board , and Marcelo Gasparino, as president, NeoFeed has learned.

Goldman Sachs, the company's largest individual shareholder, placed Raul Rosenthal and Marcos Grodetzky on the board. The two, who are Brazilian, were proposed at the last minute by the American bank.

David Castelblanco, an American who chaired the board and was a trusted associate of Goldman Sachs at Oncoclínicas, was dismissed.

The Extraordinary General Meeting (EGM) to change the board of directors of Oncoclínicas takes place less than two months after the capital increase, which brought new names to the shareholder base and converted part of the debt into shares.

In addition to Latache itself, the proposed ticket had the support of Arc Capital, Capitalo, Banco Original, Santander, and shareholders Alexandre and Arnaldo Wald, from the law firm Wald Advogados.

The change in Oncoclínicas' board of directors is another step in the company's restructuring and paves the way for a change in the company's management.

Behind the scenes, the departure of founder Bruno Ferrari from the CEO position is already considered a certainty . The expectation is that a new name to lead Oncoclínicas will be chosen by the board by the end of this month.

"We already have an executive ready to be submitted to the Board. It's someone from the healthcare sector, who should positively surprise the market," said a source familiar with the matter.

In preliminary talks with the future CEO of Oncoclínicas, it was agreed to replace the entire board of directors to bring in names trusted by the new executive. The only one who is expected to be retained is the medical director, Carlos Gil.

In an interview given to NeoFeed in September, when his departure was already being discussed, CEO Bruno Ferrari stated that he would remain in his position to lead the turnaround of Oncoclínicas.